FGFR3
About
Location: 4p16.3
Mappings
Biomarkers
FGFR3 is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| FGFR3::TACC3 | Rearrangement | 1 | 3 |
| FGFR3::BAIAP2L1 | Rearrangement | 1 | 2 |
| FGFR3 p.R248C | Somatic Variant | 1 | 3 |
| FGFR3 p.S249C | Somatic Variant | 1 | 3 |
| FGFR3 p.G370C | Somatic Variant | 1 | 3 |
| FGFR3 p.Y373C | Somatic Variant | 1 | 3 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) FDA (1) HSE (1) | FGFR3::TACC3 | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) HSE (1) | FGFR3::BAIAP2L1 | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) HSE (1) | FGFR3 p.R248C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) HSE (1) | FGFR3 p.S249C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) HSE (1) | FGFR3 p.G370C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) HSE (1) | FGFR3 p.Y373C | Bladder Urothelial Carcinoma | Erdafitinib |